William Brann, MD
Cardiovascular Disease · Evanston, WYNPI 1912087826
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 125 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 17.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $833 and has fallen 54.8% since, to $377 in 2024.
Across 125 payments — averaging $19.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$411
- Novartis$388
- Boston Scientific$370
- Merck$133
- Actelion Pharmaceuticals US, Inc.$127
- Johnson & Johnson$110
- plus $864 from 25 others
What the payments were for
- Food & beverage$2,403100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 25 | $411 |
| Novartis | 21 | $388 |
| Boston Scientific | 19 | $370 |
| Merck | 7 | $133 |
| Actelion Pharmaceuticals US, Inc. | 5 | $127 |
| Johnson & Johnson(2 entities) | 6 | $110 |
| Cvrx, Inc. | 4 | $107 |
| Irhythm Technologies, Inc. | 2 | $68 |
| Baxter Healthcare | 3 | $66 |
| Philips North America LLC | 3 | $57 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $53 |
| E.r. Squibb & Sons, L.L.C. | 3 | $51 |
| Mallinckrodt Hospital Products Inc. | 2 | $39 |
| Endologix LLC | 1 | $36 |
| Inspire Medical Systems, Inc. | 2 | $34 |
| Atricure, Inc. | 2 | $30 |
| Bardy Diagnostics, Inc. | 2 | $29 |
| Idorsia Pharmaceuticals US Inc | 2 | $29 |
| Itamar Medical Inc | 1 | $28 |
| Lexicon Pharmaceuticals, Inc. | 1 | $27 |
| Viiv Healthcare Company | 1 | $24 |
| Intuitive Surgical | 1 | $23 |
| Grifols USA, LLC | 1 | $21 |
| Medtronic | 1 | $20 |
| Active Medical, LLC | 1 | $20 |
| Bayer | 1 | $19 |
| Electromed, Inc. | 1 | $19 |
| Acell, Inc. | 1 | $19 |
| Acera Surgical, Inc. | 1 | $18 |
| Amarin Pharma, Inc. | 1 | $17 |
| Novo Nordisk | 1 | $11 |
How this compares
$2,403 in reported general payments places this provider in the 65th percentile of 22 cardiovascular disease providers in Wyoming.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 159 | $132,645 |
| FarxigaDapagliflozin Propanediol | 68 | $48,061 |
| EntrestoSacubitril/Valsartan | 49 | $42,942 |
| JardianceEmpagliflozin | 37 | $31,274 |
| XareltoRivaroxaban | 24 | $25,673 |
| Praluent PenAlirocumab | 12 | $6,102 |
| Flecainide Acetate | 54 | $2,432 |
| Metoprolol Succinate | 122 | $1,344 |
| Losartan Potassium | 154 | $1,314 |
| Nebivolol Hcl | 12 | $1,175 |
| Atorvastatin Calcium | 146 | $1,157 |
| Carvedilol | 133 | $770 |
| Amlodipine Besylate | 136 | $761 |
| Spironolactone | 123 | $758 |
| Rosuvastatin Calcium | 61 | $688 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $411 | $132,645159 claims |
| NovartisEntresto | $388 | $42,94249 claims |
| Johnson & JohnsonXarelto | $110 | $25,67324 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 22 cardiovascular disease providers in Wyoming.
Other cardiovascular disease in Evanston
- Michel SkafCasper$15K
- David GonzalezAfton$6K
- Brian KellyPowell$4K
- Robert NovickCasper$4K
- Adrian FlutureCasper$3K
- Smitha NeerukondaCheyenne$3K
- Michael BrennanSheridan$3K
- Thomas EdwardsCody$2K
- Allan WicksCasper$1K
- Isheeka EdwardsCheyenne$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.